Brief: Kinnate Biopharma Announces Recent Corporate Updates
11/10/2022 21:19
Oct 11 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. ANNOUNCES RECENT CORPORATE UPDATES,
INCLUDING ON THE ONGOING KIN-2787 MONOTHERAPY DOSE ESCALATION
FROM GLOBAL PHASE 1 TRIAL
* KINNATE BIOPHARMA - KIN-2787 CLEARED PREDICTED EFFICACIOUS
DOSE
AT 300 MG BID
* KINNATE BIOPHARMA - KIN-2787 DOSE ESCALATION CONTINUES
WITH
MAXIMUM TOLERATED DOSE NOT YET DETERMINED
* KINNATE BIOPHARMA INC - ANTICIPATES SHARING DETAILED DOSE
ESCALATION DATA IN FIRST HALF OF 2023 FOR KIN-2787
* KINNATE BIOPHARMA INC - APPROXIMATELY $262 MILLION CASH ON
HAND
AS OF SEPTEMBER 30, 2022; CASH RUNWAY INTO MID-2024
Source text for Eikon: ID:nGNX5Tx2vG
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview